Bristol Myers Squibb and Repertoire Announce $1.8B Deal to Reset Immune System in Autoimmune Patients
Bristol Myers Squibb and Repertoire Announce $1.8B Deal to Reset Immune System in Autoimmune Patients
Repertoire Immune Medicines, a biotechnology company pioneering the discovery and development of programmable T cell targeted immune medicines, announced today that it has entered a multi-year strategic collaboration with Bristol Myers Squibb (NYSE:BMY) to develop tolerizing vaccines for up to three autoimmune diseases. The collaboration aims to develop efficacious, selective, and durable treatments for patients suffering from autoimmune disease by resetting the immune system.
率先發現和開發可編程T細胞靶向免疫藥物的生物技術公司Repertoire Immune Medicines今天宣佈，它已與百時美施貴寶（紐約證券交易所代碼：BMY）建立了爲期多達三種自身免疫疾病的耐受疫苗。該合作旨在通過重置免疫系統，爲患有自身免疫疾病的患者開發有效、選擇性和持久的治療方法。
Under the terms of the agreement, Repertoire will receive an upfront payment of $65 million, and up to $1.8 billion for achieving development, regulatory and commercial milestones in addition to receiving tiered royalties.
根據協議條款，Repertoire將獲得6,500萬美元的預付款，以及高達18億美元的預付款，用於實現開發、監管和商業里程碑，此外還將獲得分級特許權使用費。
譯文內容由第三人軟體翻譯。